What Is Survodutide? Benefits, Research & Safety
A dual glucagon/GLP-1 receptor agonist under development by Boehringer Ingelheim, researched for its potential in weight management, metabolic health, and non-alcoholic steatohepatitis (NASH).
UK summary: Investigational dual GLP-1 / glucagon receptor agonist (Boehringer Ingelheim). Phase 3 trials ongoing for obesity and MASH. Not currently a UK-licensed medicine; access is via clinical trial only.
Quick Facts
Overview
Survodutide — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Investigational dual GLP-1 / glucagon receptor agonist (Boehringer Ingelheim). Phase 3 trials ongoing for obesity and MASH. Not currently a UK-licensed medicine; access is via clinical trial only.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Not approved by the MHRA. Currently an investigational compound in Phase 3 clinical trials.
- EU: Not authorised by the European Medicines Agency. Phase 3 clinical development ongoing.
- Notes: Survodutide is being evaluated in multiple Phase 3 clinical trials including the SYNCHRONIZE programme for obesity and the SYMPHONY programme for MASH. Regulatory submissions are anticipated pending completion of pivotal trials. The compound has received Fast Track designation from the FDA for MASH.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Better than tirzepatide for weight loss.
- Already available privately in the UK.
- Safe to self-administer at home.
- Compounded versions are clinically equivalent.
07Common internet claims
- Marketed by grey-market vendors as 'next-generation' obesity treatment.
- Sold by online retailers as research-only pre-launch supply.
- Promoted in 'pre-launch' weight-loss communities ahead of regulatory submission.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Available for UK private prescription” | E | No | High | Survodutide is not licensed in any jurisdiction at the time of writing. Sellers offering it operate outside the regulated framework. |
| “Better than tirzepatide for liver-fat reduction” | B | Yes | Moderate | Glucagon agonism appears to drive additional hepatic fat-loss effect in trials; comparative outcomes data are emerging. |
09Safety uncertainty score
Effectively no human safety data; safety claims are extrapolations from animal work or anecdote.
10Known adverse signals
- Phase 3 trial side-effect profile broadly similar to other incretin agents (nausea, vomiting, diarrhoea).
- Unknown long-term effects of glucagon-receptor agonism in non-trial use.
- Sterility and identity of grey-market product entirely unverified.
- Cardiovascular safety still under trial review.
11Drug-interaction uncertainty
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
13UK legal position
Not approved by the MHRA. Currently an investigational compound in Phase 3 clinical trials.
14EU legal position
Not authorised by the European Medicines Agency. Phase 3 clinical development ongoing.
15What this page cannot tell you
- Whether any 'survodutide' sold online is actually survodutide rather than a relabelled GLP-1.
- What dose is safe in any individual outside the clinical-trial protocol.
- Long-term safety in real-world use.
- Whether MHRA or NICE approval will materialise — Phase 3 outcomes are not yet final.
16Last reviewed
17Citation quality score
18Research gaps
- Phase 3 trials in obesity and MASH not yet fully published.
- Cardiovascular outcome trial pending.
- Real-world post-marketing data impossible — drug is not licensed.
19Safer alternatives / established care pathways
- Licensed Wegovy (semaglutide) or Mounjaro (tirzepatide) via NHS or GMC-registered prescriber.
- Enrolment in a registered survodutide Phase 3 trial via ClinicalTrials.gov.
- NHS Tier 2 / 3 weight management programme.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Are there UK clinical trials for survodutide I might be eligible for?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Significant body weight reduction, with clinical trials reporting mean weight loss exceeding 18% of baseline body weight over 46 weeks
- 2Substantial reduction in liver fat content, with studies showing over 80% of participants achieving clinically meaningful decreases in hepatic steatosis
- 3Improvements in glycaemic control including reduced HbA1c levels and enhanced insulin sensitivity
- 4Favourable changes in lipid profiles including reductions in triglycerides and LDL cholesterol
- 5Potential resolution of metabolic dysfunction-associated steatohepatitis (MASH) with improvement in fibrosis markers
- 6Reduction in waist circumference and visceral adiposity beyond that attributable to overall weight loss
- 7Improvements in cardiovascular risk markers including blood pressure and inflammatory biomarkers
- 8Enhanced energy expenditure through glucagon-mediated thermogenic effects, potentially supporting sustained weight management
Claim vs Evidence
How popular claims about Survodutide stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Available for UK private prescription” | E | No | High | Survodutide is not licensed in any jurisdiction at the time of writing. Sellers offering it operate outside the regulated framework. |
| “Better than tirzepatide for liver-fat reduction” | B | Yes | Moderate | Glucagon agonism appears to drive additional hepatic fat-loss effect in trials; comparative outcomes data are emerging. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Dose escalation from 0.3 mg to a target dose of up to 4.8 mg (clinical trial protocols have used stepwise escalation over several weeks to improve tolerability) |
| Frequency | Once weekly subcutaneous injection |
| Duration | Clinical trials have evaluated treatment periods of 46 weeks and longer; duration in clinical practice would be determined by prescribers |
| Notes | These protocols are based on published clinical trial designs and are not prescriptive recommendations. Survodutide is an investigational compound not approved for human use. Dose escalation schedules in trials typically involve 4-week intervals at each dose level to minimise gastrointestinal side effects. Always consult a qualified healthcare professional. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (sole route investigated in clinical trials)
| Half-Life | Stability |
|---|---|
| Approximately 60-70 hours, supporting once-weekly dosing based on clinical pharmacokinetic data | Supplied as a solution for injection in pre-filled devices in clinical trial settings; storage requirements typically 2-8°C as per investigational product handling guidelines |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Nausea, particularly during dose escalation phases (most frequently reported adverse event)
- Vomiting, generally mild to moderate and decreasing with continued treatment
- Diarrhoea, occurring more frequently at higher doses
- Decreased appetite (related to mechanism of action)
- Injection site reactions including erythema and pruritus
- Constipation reported in some participants
Rare Risks & Concerns
- Acute pancreatitis (theoretical class risk shared with GLP-1 receptor agonists)
- Cholelithiasis (gallstones) associated with rapid weight loss
- Potential hepatic effects requiring monitoring given glucagon receptor activation
- Hypoglycaemia, particularly if combined with insulin or sulphonylureas
Contraindications
- Personal or family history of medullary thyroid carcinoma (theoretical class precaution for GLP-1 agonists)
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Pregnancy and breastfeeding (no safety data available; contraindicated in clinical trials)
- Severe hepatic impairment (limited data)
- Known hypersensitivity to survodutide or any excipients
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not approved by the MHRA. Currently an investigational compound in Phase 3 clinical trials.
🇪🇺 European Union
Not authorised by the European Medicines Agency. Phase 3 clinical development ongoing.
Clinical Studies Summary
Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis.
SGLT2 inhibitor and incretin-based agents improved fibrosis in MASH, with weight loss being a significant mediator. Targeting multiple incretin pathways, especially involving glucagon receptors, may offer greater MASH resolution. Dose-dependent effects were more prominent for MASH resolution than fibrosis improvement, indicating potential weight-loss-independent anti-fibrotic pathways.
Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials.
GRAs superiorly reduce ALT levels, MRI-PDFF, and ELF. Resmetirom significantly reduces AST, HDL, and LDL levels, increases MASH resolution without worsening of fibrosis, and offers a more favourable safety profile. Both GRAs and resmetirom significantly increase adiponectin.
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.
Retatrutide and survodutide exhibit the most favourable efficacy profiles for obesity and T2DM, with acceptable safety. These findings support their potential clinical use and highlight the need for future head-to-head trials.
Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.
This study provides updated rank-order efficacy of MASH pharmacological therapies for fibrosis regression and MASH resolution. These data are helpful to inform practice and clinical trial design. Huang consults for, advises, and is on the speakers' bureau for Roche. He consults for and advises Gilead.
Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.
GLP-1RAs decreased liver fat deposition and improved histological steatosis, hepatocellular ballooning, and lobular inflammation, without worsening of fibrosis in MASLD and MASH. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints.
Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.
Retatrutide offers superior weight loss efficacy but with a higher AE risk. Dual agonists provide a favorable efficacy-safety balance. Personalized treatment selection based on patient characteristics is recommended.
Registered Trials & Regulatory Status
21 of 24 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.
A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body
Status: Recruiting · 80 participants · Boehringer Ingelheim
Conditions: Healthy, Obesity, Overweight
A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector
Status: Completed · 56 participants · Boehringer Ingelheim
Conditions: Healthy, Obesity
Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease
Status: Not Yet Recruiting · 120 participants · University Medical Center Groningen
Conditions: Chronic Kidney Disease
A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body
Status: Active Not Recruiting · 100 participants · Boehringer Ingelheim
Conditions: Healthy
A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body
Status: Completed · 16 participants · Boehringer Ingelheim
Conditions: Healthy
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity
Status: Active Not Recruiting · 64 participants · Boehringer Ingelheim
Conditions: Obesity
A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the Body
Status: Completed · 30 participants · Boehringer Ingelheim
Conditions: Healthy
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Status: Recruiting · 1,590 participants · Boehringer Ingelheim
Conditions: Metabolic Dysfunction Associated Steatohepatitis
A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity
Status: Completed · 34 participants · Boehringer Ingelheim
Conditions: Overweight, Obesity
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
Status: Recruiting · 30 participants · Boehringer Ingelheim
Conditions: Obesity
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Status: Recruiting · 1,800 participants · Boehringer Ingelheim
Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body
Status: Completed · 30 participants · Boehringer Ingelheim
Conditions: Overweight, Obesity
Adverse event reports (FDA FAERS)
Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for Survodutide?
Source research-grade Survodutide from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Survodutide
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Are there UK clinical trials for survodutide I might be eligible for?
UK regulatory & safety context
Related Peptides
Semaglutide
A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.
Learn moreLiraglutide
An earlier GLP-1 receptor agonist approved for diabetes and weight management, offering once-daily dosing with proven efficacy and safety.
Learn moreTirzepatide
A first-in-class dual GLP-1 and GIP receptor agonist achieving unprecedented weight loss of up to 22% in clinical trials, approved for type 2 diabetes and obesity treatment.
Learn moreRetatrutide
An investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, showing unprecedented weight loss of up to 24% in Phase 2 trials—potentially the most potent obesity treatment in development.
Learn more